(HealthDay News) — Researchers have developed a new tool that may predict short-term glycemic progression to type 1 diabetes. The findings were published online in Diabetes Care.

Jay M. Sosenko, MD, from the University of Miami, and colleagues utilized Diabetes Prevention Trial-Type 1 (DPT-1) data to develop and test a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes in autoantibody-positive relatives of individuals with type 1 diabetes.

The researchers found that PS6M significantly predicted type 1 diabetes (P<.001). Compared with the baseline-to-6-month difference in glucose, the area under the receiver operating characteristic curve was greater (P<.001) for the PS6M. In those with two or more autoantibodies, PS6M values were higher (30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00; P<.001 for all).

“The PS6M is an indicator of short-term glycemic progression to [type 1 diabetes] that could be a useful tool for assessing preventive treatments and biomarkers,” the researchers wrote.

Reference

  1. Sosenko JM et al. Diabetes Care. 2015;doi:10.2337/dc14-2787.